• Search History (Register)
  • MeSH Browser

Welcome to the international HTA database


Showing [22754 Records] Selected Records [0 Hits] [Clear]
Year Source Title
2009     National Institute for Health and Care Excellence (NICE) Vagus nerve stimulation for treatment-resistant depression
2005     Blue Cross Blue Shield Association (BCBS) Vagus nerve stimulation for treatment-resistant depression
1998     ECRI Vagus nerve stimulation for the treatment of intractable epilepsy
2004     National Institute for Clinical Excellence (NICE) Vagus nerve stimulation for refractory epilepsy in children
1998     Alberta Heritage Foundation for Medical Research (AHFMR) Vagus nerve stimulation for refractory epilepsy
2001     Alberta Heritage Foundation for Medical Research (AHFMR) Vagus nerve stimulation for refractory epilepsy
2006     Institute for Clinical Effectiveness and Health Policy (IECS) Vagus Nerve Stimulation for refractory epilepsy
2001     Alberta Heritage Foundation for Medical Research (AHFMR) Vagus nerve stimulation for refractory epilepsy
2008     Adelaide Health Technology Assessment (AHTA) Vagus nerve stimulation for epilepsy
2009     HAYES, Inc. Vagus nerve stimulation for epilepsy
2008     Medical Services Advisory Committee (MSAC) Vagus nerve stimulation for epilepsy
2003     HAYES, Inc. Vagus nerve stimulation for epilepsy
2007     HAYES, Inc. Vagus nerve stimulation for epilepsy
2014     HAYES, Inc. Vagus nerve stimulation for epilepsy
2009     HAYES, Inc. Vagus nerve stimulation for depression
2005     HAYES, Inc. Vagus nerve stimulation for depression
2013     HAYES, Inc. Vagus nerve stimulation for depression
2009     HAYES, Inc. Vagus nerve stimulation for depression
2018     Australian Safety and Efficacy Register of New Interventional Procedures -Surgical (ASERNIP-S) Vagus nerve stimulation for chronic major depressive episodes
2018     Australian Safety and Efficacy Register of New Interventional Procedures -Surgical (ASERNIP-S) Vagus nerve stimulation for chronic major depressive episodes
2001     Canadian Coordinating Office for Health Technology Assessment (CCOHTA) Vagus nerve stimulation (VNS) for treatment-resistant depression
2000     Alberta Heritage Foundation for Medical Research (AHFMR) Vagus nerve stimulation
2015     Australian Safety and Efficacy Register of New Interventional Procedures -Surgical (ASERNIP-S) Vagus nerve blocking and gastric artery embolisation for obesity
1997     Alberta Heritage Foundation for Medical Research (AHFMR) Vaginoplasty in male-female transsexuals and criteria for sex reassignment surgery
2023     National Institute for Health and Care Excellence (NICE) Vaginal transluminal endoscopic hysterectomy and adnexal surgery for benign gynaecological conditions. NICE interventional procedures guidance 774
2013     Canadian Agency for Drugs and Technologies in Health (CADTH) Vaginal preparation prior to cesarean delivery: clinical evidence
2021     Ontario Health Vaginal pessaries for pelvic organ prolapse and stress urinary incontinence
2014     Canadian Agency for Drugs and Technologies in Health (CADTH) Vaginal micronized progesterone capsules for the prevention of miscarriage and preterm birth: a review of the clinical evidence
2000     HAYES, Inc. Vaginal hormonal cytology for the diagnosis and management of menopause
2010     Adelaide Health Technology Assessment (AHTA) Vaginal brachytherapy for treatment of women with high-intermediate risk of endometrial cancer
1993     Danish Institute for Health Services Research (DSI) Vaginal bleeding disorders. Consensus statement
2010     Agency for Healthcare Research and Quality (AHRQ) Vaginal birth after cesarean: new insights
2003     Agency for Healthcare Research and Quality (AHRQ) Vaginal birth after Cesarean (VBAC)
2005     Technology Assessment Unit of the McGill University Health Centre (MUHC) Vacuum-assisted wound closure therapy (V.A.C (R))
2000     ECRI Vacuum-assisted wound closure for chronic and acute wounds
2003     Australian Safety and Efficacy Register of New Interventional Procedures -Surgical (ASERNIP-S) Vacuum-assisted closure for the management of wounds: an accelerated systematic review
2006     Agence d'évaluation des technologies et des modes d'intervention en santé (AETMIS) Vacuum-assisted breast biopsy
2003     Canadian Coordinating Office for Health Technology Assessment (CCOHTA) Vacuum assisted wound closure therapy
2004     Medical Advisory Secretariat (MAS) Vacuum assisted closure therapy for wound care
2003     Quality Improvement Scotland (NHS QIS ) Vacuum assisted closure (VAC) for wound healing
2005     Canadian Coordinating Office for Health Technology Assessment (CCOHTA) Vaccines for prevention of human papillomavirus infection
2015     NIHR Health Technology Assessment programme Vaccines for preventing influenza in healthy adults (A060)
2005     Canadian Coordinating Office for Health Technology Assessment (CCOHTA) Vaccines for metastatic hormone-refractory prostate cancer
2006     Canadian Coordinating Office for Health Technology Assessment (CCOHTA) Vaccines for HIV
2006     Canadian Coordinating Office for Health Technology Assessment (CCOHTA) Vaccines for avian influenza
2012     Belgian Health Care Knowledge Centre (KCE) Vaccine safety surveillance in Belgium : place and limits of a background rate approach
2006     Canadian Coordinating Office for Health Technology Assessment (CCOHTA) Vaccine for herpes zoster
2006     Canadian Coordinating Office for Health Technology Assessment (CCOHTA) Vaccine for herpes simplex
2010     NIHR Health Technology Assessment programme Vaccine effectiveness in pandemic influenza - primary care reporting (VIPER): an observational study to assess the effectiveness of the pandemic influenza A (H1N1)v vaccine
2000     Health Council of the Netherlands Gezondheidsraad (GR) Vaccination policies in case of an influenza pandemic
2011     Health Council of the Netherlands Gezondheidsraad (GR) Vaccination of young children against tuberculosis
2013     Health Council of the Netherlands Gezondheidsraad (GR) Vaccination of infants against pneumococcal infections (3)
2003     Health Council of the Netherlands Gezondheidsraad (GR) Vaccination of children against hepatitis B
2020     National Authority for Assessment and Accreditation in Healthcare (INEAS) Vaccination contre la grippe dans le contexte particulier de la pandémie COVID-19 : intérêt et populations prioritaires
2015     Health Council of the Netherlands Gezondheidsraad (GR) Vaccination against pertussis: aims and strategy
2004     Health Council of the Netherlands Gezondheidsraad (GR) Vaccination against pertussis
2009     Health Council of the Netherlands Gezondheidsraad (GR) Vaccination against pandemic influenza A/H1N1 2009: target groups and prioritisation
1991     Health Council of the Netherlands Gezondheidsraad (GR) Vaccination against Haemophilus influenzae type b
2008     Health Council of the Netherlands Gezondheidsraad (GR) Vaccination against cervical cancer
1994     Health Council of the Netherlands Gezondheidsraad (GR) UV radiation from sunlight
2003     Israel Center for Technology Assessment in Health Care (ICTAHC) Utilization patterns of CT and MRI in Israel
2005     Agencia de Evaluacion de Tecnologias Sanitarias (AETS) Utilization of information and communication technology in managing chronic diseases: a systematic review IPE-05/45 (Public report)
2006     Medical Advisory Secretariat (MAS) Utilization of DXA bone mineral densitometry in Ontario: an evidence-based analysis
2005     Institute for Clinical Evaluative Sciences (ICES) Utilization of CT and MRI scanning among cancer patients in Ontario, 1993-2002
2015     Andalusian Health Technology Assessment Area (AETSA) Utility of QF_PCR in prenatal diagnosis of fetal aneuploidies
2017     Andalusian Health Technology Assessment Area (AETSA) Utility of pulmonary metastases resection for colorectal cancer
2009     Institute for Clinical Effectiveness and Health Policy (IECS) Utility of MuSK antibodies in patients with myastenia gravis
2008     Agency for Healthcare Research and Quality (AHRQ) Utility of monitoring mycophenolic acid in solid organ transplant patients
2017     Andalusian Health Technology Assessment Area (AETSA) Utility of exome sequencing for diagnosed dismorphic syndromes, with or without intellectual disabilities. Literature review
2002     Agency for Healthcare Research and Quality (AHRQ) Utility of blood pressure monitoring outside of the clinic setting
2019     NIHR Health Technology Assessment programme Uterotonic drugs to prevent postpartum haemorrhage: a network meta-analysis
2019     NIHR Health Technology Assessment programme Uterotonic drugs to prevent postpartum haemorrhage: a network meta-analysis
2001     ECRI Uterine fibroid embolization for the treatment of fibroids
2003     Institute for Clinical Systems Improvement (ICSI) Uterine artery embolization for uterine fibroids
2002     Blue Cross Blue Shield Association (BCBS) Uterine artery embolization for treatment of symptomatic uterine fibroids
2005     HAYES, Inc. Uterine artery embolization for treatment of fibroids
2003     HAYES, Inc. Uterine artery embolization for treatment of fibroids
2002     Canadian Coordinating Office for Health Technology Assessment (CCOHTA) Uterine artery embolization for the treatment of fibroids
2006     Institute for Clinical Effectiveness and Health Policy (IECS) Uterine artery embolization for the management of uterine fibroids
2009     HAYES, Inc. Uterine artery embolization
2006     Adelaide Health Technology Assessment (AHTA) Uterine artery embolisation for the treatment of symptomatic uterine fibroids
2004     National Institute for Clinical Excellence (NICE) Uterine artery embolisation for the treatment of fibroids
2003     Wessex Institute for Health Research and Development (WIHRD) Uterine artery embolisation for fibroids
2003     National Institute for Clinical Excellence (NICE) Uterine artery embolisation for fibroids
2010     National Institute for Health and Care Excellence (NICE) Uterine artery embolisation for fibroids
2005     Agency for Healthcare Research and Quality (AHRQ) Usual care in the management of chronic wounds: a review of the recent literature
2020     National Institute for Health and Care Excellence (NICE) Ustekinumab for treating moderately to severely active ulcerative colitis. NICE technology appraisal guidance 633
2015     National Institute for Health and Care Excellence (NICE) Ustekinumab for treating active psoriatic arthritis. NICE technology appraisal guidance 340
2013     NIHR Health Technology Assessment programme Ustekinumab for treating active and progressive psoriatic arthritis
2009     NIHR Health Technology Assessment programme Ustekinumab for the treatment of moderate to severe psoriasis
2017     Agency for Care Effectiveness (ACE) Ustekinumab for the treatment of chronic plaque psoriasis and psoriatic arthritis
2009     National Institute for Health and Care Excellence (NICE) Ustekinumab for the treatment of adults with moderate to severe psoriasis
2019     European Network for Health Technology Assessment (EUnetHTA) Ustekinumab for the treatment of adult patients with moderately to severely active ulcerative colitis (uc) who have had an inadequate response with, lost response to or were intolerant to either conventional therapy or a biologic or have medical contraindications to such therapies
2017     National Institute for Health and Care Excellence (NICE) Ustekinumab for moderately to severely active Crohn's disease after previous treatment. NICE technology appraisal guidance 456
2010     NIHR Horizon Scanning Centre (NIHR HSC) Ustekinumab (Stelara) for psoriatic arthritis - second line after disease modifying anti-rheumatic drugs (DMARDs)
2012     NIHR Horizon Scanning Centre (NIHR HSC) Ustekinumab (Stelara) for psoriatic arthritis
2013     NIHR Horizon Scanning Centre (NIHR HSC) Ustekinumab (Stelara) for plaque psoriasis in adolescents
2014     NIHR Horizon Scanning Centre (NIHR HSC) Ustekinumab (Stelara) for Crohn's disease
2016     HAYES, Inc. Ustekinumab (Stelara; Janssen Biotech Inc.) for treatment of psoriatic arthritis
2014     Canadian Agency for Drugs and Technologies in Health (CADTH) Ustekinumab (Stelara — Janssen Inc.) indication: psoriatic arthritis